Intravaginal Administration of Interleukin 12 during Genital Gonococcal Infection in Mice Induces Immunity to Heterologous Strains of Neisseria gonorrhoeae

• DOI: 10.1128/msphere.00421-17
• Publication Date: 2018-01-30T12:31:56Z
• Authors: Yingru Liu; Julianny Perez; Laura A. Hammer; Heather C. Gallagher; Magdia De Jesus; Nejat K. Egilmez; Michael W. Russell
• Keywords: 03 medical and health sciences; 0302 clinical medicine; genital tract immunity; microencapsulation; interleukin 12; adaptive immunity; Microbiology; Neisseria gonorrhoeae; QR1-502; Research Article; 3. Good health

Genital infection with Neisseria gonorrhoeae (gonorrhea) is a significant cause of reproductive tract morbidity in women, leading to pelvic inflammatory disease, tubal factor infertility, and increased risk for ectopic pregnancy. WHO estimates that 78 million new infections occur annually worldwide. In the United States, >350,000 cases are reported annually, but the true incidence is probably >800,000 cases/year. Increasing resistance to currently available antibiotics raises concern that gonorrhea might become untreatable. Infection does not induce a state of immune protection against reinfection. Previous studies have shown that N. gonorrhoeae suppresses the development of adaptive immune responses by mechanisms dependent on the regulatory cytokines TGF-β and IL-10. This study shows that intravaginal treatment of gonococcal infection in female mice with microencapsulated IL-12 induces persisting anamnestic immunity against reinfection with N. gonorrhoeae , even of antigenically diverse strains, dependent on T-cell production of IFN-γ and B-cell production of antibodies.